Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.
Our company’s unique strengths include our modular lipid nanoparticle delivery system and our determined focus on product development.
Each one of us together for patients
We believe our modular approach to selecting our in vivo and ex vivo programs positions us to build a full-spectrum genome editing company, with a pipeline across a range of indications. This approach enables us to generate a wealth of data that opens the potential therapeutic applications of the CRISPR/Cas9 technology across a broad range of diseases.
#ICYMI Intellia CSO, @LauraSepplore, was recently a guest on @BioAgilytix’s podcast, Molecular Moments, discussing her path from Argentina to the U.S., gene therapy vs. #genomeediting and the work we’re doing at Intellia. Listen here: https://t.co/vnXn2AC4Wd https://t.co/UKS9Jgwn5N
A warm welcome to Georgia Keresty, Ph.D., M.P.H., to Intellia’s Board of Directors! We look forward to drawing on her insights as a successful industry leader to help advance our programs toward the clinic: https://t.co/2SFlI7zpuD #CRISPR https://t.co/sLOMnf1LTN